Clinical Trials Logo

Clinical Trial Summary

Anti-cancer immunotherapy, one of the therapeutic revolutions of recent years. It is based on the use of antibodies that block immune system checkpoints that have been hijacked by cancer cells to benefit themselves. Blocking these checkpoints, such as PD-1, unleashes the action of anti-cancer T cells that can then destroy the tumor. The efficacy of these targeted therapies is significant, with an average 40% response rate in patients with metastatic cancers.Immune checkpoint inhibitors (ICIs) are becoming a 1st line therapy in many oncology indications due to their therapeutic line in many oncology indications due to their favorable effect on the prognosis of various prognosis of various cancers Since checkpoints play a key role in controlling the intensity and duration of an immune response, their immune response, therefore, their inhibition exposes to adverse inflammatory or autoimmune effects inflammatory or autoimmune adverse effects that can be severe and sometimes lethal.Most side effects of ICIs occur within the first few months after initiation of treatment. The toxicity of immunotherapy is immunological, all organs including the heart can be including the heart, can be affected. Cardiac autoimmune involvement in ICIs can involve the myocardium, pericardium, and/or vascular endothelium. These entities may be interrelated or, on the contrary, isolated. In the last 5 years, the number of described cases of myocarditis associated with ICIstreatment has increased. Their incidence remains low, estimated between 0.5 and 2%. This probably represents the most serious cardiovascular complication, as the mortality attributed to it reaches almost 50%. In recent years MRI has become very important in the noninvasive diagnosis of acute myocarditis. The latest update of the Lake Louise criteria in 2018 has thus confirmed cardiac MRI in its first place among noninvasive examinations for the diagnosis of myocarditis with a sensitivity of 87.5%, a specificity of 96.2%, and a positive predictive value of 97.2%.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05125965
Study type Interventional
Source Centre Chirurgical Marie Lannelongue
Contact Arshid Azarine, MD
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date November 15, 2021
Completion date November 15, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04085718 - FDG-PET/CT Images Comparing to MRI and Endomyocardial Biopsy in Myocarditis
Recruiting NCT04612296 - The Heart Hive - Cardiomyopathy Study
Recruiting NCT04673409 - CMR Imaging of Autoimmune Diseases
Recruiting NCT03777839 - PET-FDG in Myocarditis
Recruiting NCT04444128 - IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
Recruiting NCT03801681 - ARrhythmias in MYocarditis
Completed NCT04413071 - Cardiac COVID-19 Health Care Workers
Not yet recruiting NCT04844151 - Acute Myocarditis Registry With Prognostic, Histologic, Immunologic, Biological, Imaging and Clinical Assessment
Completed NCT02299856 - Cardiac Magnetic Resonance in Acute Myocarditis N/A
Recruiting NCT01089036 - Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in Extracorporeal Membrane Oxygenation (ECMO) Patients N/A
Completed NCT00693134 - Role of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Children With Myocarditis N/A
Recruiting NCT04320017 - Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19
Recruiting NCT04367350 - Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
Active, not recruiting NCT04498065 - MYocardial DOmmages Related to COVID-19
Recruiting NCT02590341 - Myocarditis Registry for Children and Adolescents - MYKKE N/A
Completed NCT04936503 - Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19 N/A
Enrolling by invitation NCT03527342 - Sahlgrenska Cardiomyopathy Project
Completed NCT00000524 - Myocarditis Treatment Trial Phase 2
Recruiting NCT03347760 - Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis N/A
Recruiting NCT04521790 - Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management